{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-025698","form_type":"8-K/A","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.143021+00:00","generated_at":"2026-06-17T06:48:17.849559+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ABVC BioPharma FY2022 revenue $970K (+173%) but net loss widens to $16.3M","bullets":["Revenue $969,783 (up 173% from $355,797) driven by contract services with Rgene.","Net loss $16.3M vs $12.0M in 2021; operating expenses $15.8M (up $3.7M).","Cash dropped to $85K from $5.8M; working deficit of $2.8M.","Pipeline: Vitargus Phase II expected completion end of 2023; ABV-1505 ADHD enrollment ongoing.","ABV-1601 Phase I at Cedars-Sinai initiated; ABV-1504 MDD meeting with FDA for Phase III."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-025698","json":"https://secwatch.observer/filing/0001213900-23-025698.json","markdown":"https://secwatch.observer/filing/0001213900-23-025698.md","text":"https://secwatch.observer/filing/0001213900-23-025698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023025698/0001213900-23-025698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023025698/ea176287-8ka_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:48:17.849559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9736cd8974e367c5c10218d800765ec72eb0a98f","claim":"ABVC BIOPHARMA, INC. reported the fiscal year ended December 31, 2022 results: revenue $969,783, net income $16,312,374.","evidence_excerpt":"and operating results for the fiscal year ended December 31, 2022. Full Year 2022 Financial Results All comparisons are made on a year-over-year basis. ● Revenues . We generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively. The increase of $613,986, or approximately 173%, was primarily caused by the increase in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023025698/0001213900-23-025698-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$969,783"},{"label":"Net income","value":"$16,312,374"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}